Inhibition of Angiogenesis by Treatment with Cold Atmospheric Plasma as a Promising Therapeutic Approach in Oncology.
apoptosis
cell migration
cold atmospheric plasma
endothelial cells VEGF
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Sep 2020
26 Sep 2020
Historique:
received:
15
09
2020
revised:
23
09
2020
accepted:
24
09
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
26
2
2021
Statut:
epublish
Résumé
Cold atmospheric plasma (CAP) is increasingly used in the field of oncology. Many of the mechanisms of action of CAP, such as inhibiting proliferation, DNA breakage, or the destruction of cell membrane integrity, have been investigated in many different types of tumors. In this regard, data are available from both in vivo and in vitro studies. Not only the direct treatment of a tumor but also the influence on its blood supply play a decisive role in the success of the therapy and the patient's further prognosis. Whether the CAP influences this process is unknown, and the first indications in this regard are addressed in this study. Two different devices, kINPen and MiniJet, were used as CAP sources. Human endothelial cell line HDMEC were treated directly and indirectly with CAP, and growth kinetics were performed. To indicate apoptotic processes, caspase-3/7 assay and TUNEL assay were used. The influence of CAP on cellular metabolism was examined using the MTT and glucose assay. After CAP exposure, tube formation assay was performed to examine the capillary tube formation abilities of HDMEC and their migration was messured in separate assays. To investigate in a possible mutagenic effect of CAP treatment, a hypoxanthine-guanine-phosphoribosyl-transferase assay with non malignant cell (CCL-93) line was performed. The direct CAP treatment of the HDMEC showed a robust growth-inhibiting effect, but the indirect one did not. The MMT assay showed an apparent reduction in cell metabolism in the first 24 h after CAP treatment, which appeared to normalize 48 h and 72 h after CAP application. These results were also confirmed by the glucose assay. The caspase 3/7 assay and TUNEL assay showed a significant increase in apoptotic processes in the HDMEC after CAP treatment. These results were independent of the CAP device. Both the migration and tube formation of HDMEC were significant inhibited after CAP-treatment. No malignant effects could be demonstrated by the CAP treatment on a non-malignant cell line.
Sections du résumé
BACKGROUND
BACKGROUND
Cold atmospheric plasma (CAP) is increasingly used in the field of oncology. Many of the mechanisms of action of CAP, such as inhibiting proliferation, DNA breakage, or the destruction of cell membrane integrity, have been investigated in many different types of tumors. In this regard, data are available from both in vivo and in vitro studies. Not only the direct treatment of a tumor but also the influence on its blood supply play a decisive role in the success of the therapy and the patient's further prognosis. Whether the CAP influences this process is unknown, and the first indications in this regard are addressed in this study.
METHODS
METHODS
Two different devices, kINPen and MiniJet, were used as CAP sources. Human endothelial cell line HDMEC were treated directly and indirectly with CAP, and growth kinetics were performed. To indicate apoptotic processes, caspase-3/7 assay and TUNEL assay were used. The influence of CAP on cellular metabolism was examined using the MTT and glucose assay. After CAP exposure, tube formation assay was performed to examine the capillary tube formation abilities of HDMEC and their migration was messured in separate assays. To investigate in a possible mutagenic effect of CAP treatment, a hypoxanthine-guanine-phosphoribosyl-transferase assay with non malignant cell (CCL-93) line was performed.
RESULTS
RESULTS
The direct CAP treatment of the HDMEC showed a robust growth-inhibiting effect, but the indirect one did not. The MMT assay showed an apparent reduction in cell metabolism in the first 24 h after CAP treatment, which appeared to normalize 48 h and 72 h after CAP application. These results were also confirmed by the glucose assay. The caspase 3/7 assay and TUNEL assay showed a significant increase in apoptotic processes in the HDMEC after CAP treatment. These results were independent of the CAP device. Both the migration and tube formation of HDMEC were significant inhibited after CAP-treatment. No malignant effects could be demonstrated by the CAP treatment on a non-malignant cell line.
Identifiants
pubmed: 32993057
pii: ijms21197098
doi: 10.3390/ijms21197098
pmc: PMC7582386
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Plasma Gases
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
PLoS One. 2015 Jun 17;10(6):e0126313
pubmed: 26083405
Eur J Clin Chem Clin Biochem. 1995 Nov;33(11):813-23
pubmed: 8620058
Z Kardiol. 2000 Mar;89(3):206-18
pubmed: 10798277
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2005 May;17(5):268-72
pubmed: 15877949
Biol Trace Elem Res. 2017 Feb;175(2):428-439
pubmed: 27377067
GMS Hyg Infect Control. 2017 Aug 08;12:Doc10
pubmed: 28840090
Front Plant Sci. 2020 Feb 14;11:77
pubmed: 32117403
Genome Biol. 2005;6(2):209
pubmed: 15693956
Int J Mol Med. 2014 Oct;34(4):941-6
pubmed: 25050490
J Gastrointest Oncol. 2017 Jun;8(3):499-512
pubmed: 28736637
Environ Mol Mutagen. 2017 Apr;58(3):172-177
pubmed: 28370324
Med Clin North Am. 2010 Jul;94(4):835-52, xiii
pubmed: 20609866
PLoS One. 2018 Oct 12;13(10):e0204916
pubmed: 30312292
Oncol Rep. 2017 Aug;38(2):625-636
pubmed: 28656259
Anticancer Res. 2017 Mar;37(3):1031-1038
pubmed: 28314261
Ther Adv Med Oncol. 2018 Jul 20;10:1758835918786475
pubmed: 30046358
Anticancer Res. 2017 Dec;37(12):6739-6744
pubmed: 29187451
Int J Mol Sci. 2020 Jun 23;21(12):
pubmed: 32585948
PLoS One. 2015 Dec 14;10(12):e0144968
pubmed: 26661594
Cancer Gene Ther. 2010 Oct;17(10):700-7
pubmed: 20559333
J Basic Microbiol. 1999;39(2):103-8
pubmed: 10335603
Onco Targets Ther. 2016 Sep 28;9:5911-5917
pubmed: 27729800
In Vivo. 2019 Jul-Aug;33(4):1011-1026
pubmed: 31280189
Oxid Med Cell Longev. 2019 Sep 3;2019:3873928
pubmed: 31565150
J Biol Chem. 2001 Feb 2;276(5):3222-30
pubmed: 11058584
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Free Radic Biol Med. 2017 Sep;110:72-80
pubmed: 28571751
PLoS One. 2010 Jul 29;5(7):e11860
pubmed: 20686621
Rom J Morphol Embryol. 2018;59(2):455-467
pubmed: 30173249
Am J Physiol Cell Physiol. 2002 May;282(5):C1181-90
pubmed: 11940533
J Exp Med. 1995 Aug 1;182(2):367-77
pubmed: 7629499
PLoS One. 2015 Jul 01;10(7):e0130350
pubmed: 26132846
PLoS One. 2013 Sep 11;8(9):e73741
pubmed: 24040051
Cancer Res. 2002 Jul 15;62(14):4123-31
pubmed: 12124351
Nat Rev Cancer. 2002 Jan;2(1):48-58
pubmed: 11902585
Sci Rep. 2019 Oct 2;9(1):14210
pubmed: 31578342
Recent Prog Horm Res. 2000;55:15-35; discussion 35-6
pubmed: 11036931
Br J Cancer. 2015 Mar 3;112(5):948-56
pubmed: 25602964
Sci Rep. 2016 Feb 03;6:20332
pubmed: 26838306
Exp Dermatol. 2013 Apr;22(4):284-9
pubmed: 23528215
Mutat Res. 1981 Sep;87(2):81-142
pubmed: 7035931
Nat Rev Cancer. 2002 Oct;2(10):727-39
pubmed: 12360276
J Cell Biol. 2005 May 23;169(4):681-91
pubmed: 15911882
Oncol Rep. 2016 Jan;35(1):359-65
pubmed: 26531153
Cancer Metastasis Rev. 1982;1(4):289-317
pubmed: 6224552
Cancers (Basel). 2020 Jan 22;12(2):
pubmed: 31979114
Stem Cells. 2011 Jun;29(6):888-94
pubmed: 21557392
Science. 1989 Dec 8;246(4935):1306-9
pubmed: 2479986
Biomol Ther (Seoul). 2014 Nov;22(6):477-90
pubmed: 25489414
Oncogene. 2018 Feb 8;37(6):722-731
pubmed: 29059175
PLoS One. 2014 May 30;9(5):e98652
pubmed: 24878760
Cancer Res. 1999 Jan 15;59(2):487-90
pubmed: 9927067
J Wound Care. 2015 May;24(5):196, 198-200, 202-3
pubmed: 25970756
Oncol Lett. 2020 Jan;19(1):283-290
pubmed: 31897140
Dev Cell. 2009 Feb;16(2):167-79
pubmed: 19217420
Adv Ther. 2016 Jun;33(6):894-909
pubmed: 27142848
Cancer Res. 2009 May 15;69(10):4537-44
pubmed: 19435903
Curr Opin Cell Biol. 2010 Oct;22(5):617-25
pubmed: 20817428
Semin Oncol. 2001 Dec;28(6):536-42
pubmed: 11740806
Nat Commun. 2018 Feb 28;9(1):887
pubmed: 29491397
PLoS One. 2011 Jan 21;6(1):e16270
pubmed: 21283714
Int J Cancer. 2014 Apr 1;134(7):1517-28
pubmed: 23754175
PLoS One. 2019 Apr 9;14(4):e0215099
pubmed: 30964925
Mol Cancer Ther. 2014 Dec;13(12):3123-36
pubmed: 25319392
Oncotarget. 2017 Feb 28;8(9):15977-15995
pubmed: 27845910
Cell Cycle. 2003 May-Jun;2(3):192-3
pubmed: 12734422
J Dermatol Sci. 2014 May;74(2):106-15
pubmed: 24507936